ASCO GU 2024

BRCAAway - practice changing or hypothesis generating…

Is "more" always better?

Cabo + IO: Interesting but not practice changing?!

Salvage radiation with anti-androgen superior to…

Higher radiation is effective in high-risk PCA

Long-term dose escalation - Therapy in high-risk…

What about the clinical benefit?

Olaparib + Arbiraterone better compared to either alone

First positive study of IO therapy in mCRPC

Still a difficult time for androgenic inhibitors in…

Combination NHT + PARP makes sense

Localized PCa - news for radiotherapy and biochemical…

Relugolix combined with androgen signaling in real word…

BRCAaway - PARP combination study

Gleason 3+3 - cancer or not?

Therapy Intensification Still Neglected in mHSPC

Enzalutamide therapy as option for biochemical…

Stockholm3 validated in multiethnic cohort

Combination of cabozantinib & checkpoint inhibitor

Insights and news for mCRPC

Dose de-escalation in different ways

Quality of life under intensive therapy

Evaluating the recombination-repair mutations in…

Cognitive function in ART treatment

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi) Orta…

SEPTA calismasi: Stockholm3 un multietnik hasta…

Post-RP salvage radyoterapi hormonoterapi ile konbine…

BRCAAway - PARP hämmare, abiraterone eller i…

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

Gleason 3+3 ska vi kalla de cancer eller inte?

Kognitiv påverkan av abirateron och enzalutamid?

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO…

Une période encore difficile pour les inhibiteurs…

The emerging field of biomarkers in bladder cancer

New standard of care, but still open questions!

Advances in (neo)-adjuvant treatment in urothelial…

Update on EV-302

EV as standard in 3rd line mUC

EV + Pembro new first-line standard in localized…

Pembrolizumab adjuvant in bladder cancer

Biomarker update

Perioperative adjuvant therapy in urothelial cancer

MIBC: adjuvant PD1 - all set?!

Should we start forgetting the Galsky Criteria in…

Adjuvant Nivolumab Shows Promise in Boosting Long-Term…

Update M1 urothelial cancer

Another success for an ICI?

ASCO GU24 - Highlights in Bladder cancer

Highlights in bladder cancer at ASCO GU24

Adjuvant therapy in urothelial carcinoma : is the…

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Novedades sobre EV-302

¿Deberíamos empezar a olvidarnos de los Criterios de…

Encore un succès pour une ICI ?

Terapia adyuvante perioperatoria en el cáncer de vejiga

Subcutaneous vs. intravenous application: ready for…

Trial updates at ASCO GU24: Are the follow-up data…

Adjuvant therapy in kidney cancer: Is immunotherapy the…

Cabozantinib Plus Atezolizumab in Adrenocortical…

Subcutaneous Nivolumab Matches IV Formulation in Clear…

Better QoL with Belzutifan

Practice changing adjuvant therapy?!

Tumorburden and outcome

Highlights in kidney cancer at ASCO GU24

Long-Term Data on NIVO+IPI in aRCC

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark…

Durable effects of Ipi-Nivo

Perioperative treatment in renal cell carcinoma - did…

Long-term outcome

Long-term follow-up of first-line trials

ASCO GU24 - Highlights in renal cell carcinoma

Belzutifan: Updates on QoL

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24